Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject^™ in Patients with Gorlin Syndrome

Medicus Pharma, Ltd. announced a strategic collaboration with the Gorlin Syndrome Alliance to advance compassionate access to SKINJECT^™, the Company’s investigational doxorubicin containing microneedle arrays for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.